Insights into the current status of privileged N-heterocycles as antileishmanial agents

Leishmania, one of the most important neglected tropical diseases, is endemic in several regions of the world and hence regarded as a serious threat to public health. Major difficulties with current chemotherapeutic agents raise issues such as toxicity, resistance, cost and other side effects. These...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular diversity 2020-05, Vol.24 (2), p.525-569
Hauptverfasser: Razzaghi-Asl, Nima, Sepehri, Saghi, Ebadi, Ahmad, Karami, Pari, Nejatkhah, Negin, Johari-Ahar, Mohammad
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 569
container_issue 2
container_start_page 525
container_title Molecular diversity
container_volume 24
creator Razzaghi-Asl, Nima
Sepehri, Saghi
Ebadi, Ahmad
Karami, Pari
Nejatkhah, Negin
Johari-Ahar, Mohammad
description Leishmania, one of the most important neglected tropical diseases, is endemic in several regions of the world and hence regarded as a serious threat to public health. Major difficulties with current chemotherapeutic agents raise issues such as toxicity, resistance, cost and other side effects. These issues necessitate development of potentially new chemical entities against diverse leishmanial species. Numerous natural and synthetic new antileishmanial molecules have been described for disease management. Careful inspection of scientific reports revealed that considerable amount of promising antileishmanial agents belonged to the nitrogen-containing heterocycles such as quinoline, triazole, pyrazole, imidazole, indole, pyrimidine, β-carboline, quinoxaline, quinazoline and benzimidazole. In this regard, enormous chemical data provide the opportunity for systematic elucidation of structural requirements against different leishmanial species. Within this representation, insights into the current status of privileged N -heterocycles as antileishmanial agents with particular emphasis on structure activity relationships are reviewed. Graphical abstract
doi_str_mv 10.1007/s11030-019-09953-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2216285254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2215418181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-c10c36efcbd233c8ea5e0f0f72a7867bc403de433026d4f381db14f6598ec9863</originalsourceid><addsrcrecordid>eNp9kF9LHDEUxYNUuqv2C_hQAn3pS_TeyWT-PBaxKkh9UfQtZDN3dmeZndnmZgS_fbOuVuhDSSCB-zsnOUeIU4QzBCjPGRE0KMBaQV0brfIDMUdTamUAnz6lu65QYV3jTBwxrwGSDPVnMdMIWWVMNRePNwN3y1Vk2Q1xlHFF0k8h0BAlRxcnlmMrt6F77npaUiN_qRVFCqN_8T2xdGkPMc06Xm3c0LleumUS84k4bF3P9OXtPBYPPy_vL67V7d3VzcWPW-V1aaLyCF4X1PpFk2ntK3KGoIW2zFxZFeXC56AbyrWGrGjyNuVpFpi3hakr8nVV6GPxfe-7DePviTjaTcee-t4NNE5sswyLFDUzeUK__YOuxykM6Xc7yuRYpZWobE_5MDIHam1Kv3HhxSLYXe12X7tNtdvX2u3O-uub9bTYUPNX8t5zAvQe4DQalhQ-3v6P7R_VE42j</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2215418181</pqid></control><display><type>article</type><title>Insights into the current status of privileged N-heterocycles as antileishmanial agents</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Razzaghi-Asl, Nima ; Sepehri, Saghi ; Ebadi, Ahmad ; Karami, Pari ; Nejatkhah, Negin ; Johari-Ahar, Mohammad</creator><creatorcontrib>Razzaghi-Asl, Nima ; Sepehri, Saghi ; Ebadi, Ahmad ; Karami, Pari ; Nejatkhah, Negin ; Johari-Ahar, Mohammad</creatorcontrib><description>Leishmania, one of the most important neglected tropical diseases, is endemic in several regions of the world and hence regarded as a serious threat to public health. Major difficulties with current chemotherapeutic agents raise issues such as toxicity, resistance, cost and other side effects. These issues necessitate development of potentially new chemical entities against diverse leishmanial species. Numerous natural and synthetic new antileishmanial molecules have been described for disease management. Careful inspection of scientific reports revealed that considerable amount of promising antileishmanial agents belonged to the nitrogen-containing heterocycles such as quinoline, triazole, pyrazole, imidazole, indole, pyrimidine, β-carboline, quinoxaline, quinazoline and benzimidazole. In this regard, enormous chemical data provide the opportunity for systematic elucidation of structural requirements against different leishmanial species. Within this representation, insights into the current status of privileged N -heterocycles as antileishmanial agents with particular emphasis on structure activity relationships are reviewed. Graphical abstract</description><identifier>ISSN: 1381-1991</identifier><identifier>EISSN: 1573-501X</identifier><identifier>DOI: 10.1007/s11030-019-09953-4</identifier><identifier>PMID: 31028558</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Animals ; Antiprotozoal Agents - chemistry ; Antiprotozoal Agents - pharmacology ; Antiprotozoal Agents - therapeutic use ; Biochemistry ; Biomedical and Life Sciences ; Comprehensive Review ; Health risks ; Heterocyclic Compounds - chemistry ; Heterocyclic Compounds - pharmacology ; Heterocyclic Compounds - therapeutic use ; Humans ; Inspection ; Leishmania - drug effects ; Leishmaniasis - drug therapy ; Life Sciences ; Organic Chemistry ; Pharmacy ; Polymer Sciences ; Public health ; Toxicity</subject><ispartof>Molecular diversity, 2020-05, Vol.24 (2), p.525-569</ispartof><rights>Springer Nature Switzerland AG 2019</rights><rights>Springer Nature Switzerland AG 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-c10c36efcbd233c8ea5e0f0f72a7867bc403de433026d4f381db14f6598ec9863</citedby><cites>FETCH-LOGICAL-c375t-c10c36efcbd233c8ea5e0f0f72a7867bc403de433026d4f381db14f6598ec9863</cites><orcidid>0000-0001-6127-2497</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11030-019-09953-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11030-019-09953-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31028558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Razzaghi-Asl, Nima</creatorcontrib><creatorcontrib>Sepehri, Saghi</creatorcontrib><creatorcontrib>Ebadi, Ahmad</creatorcontrib><creatorcontrib>Karami, Pari</creatorcontrib><creatorcontrib>Nejatkhah, Negin</creatorcontrib><creatorcontrib>Johari-Ahar, Mohammad</creatorcontrib><title>Insights into the current status of privileged N-heterocycles as antileishmanial agents</title><title>Molecular diversity</title><addtitle>Mol Divers</addtitle><addtitle>Mol Divers</addtitle><description>Leishmania, one of the most important neglected tropical diseases, is endemic in several regions of the world and hence regarded as a serious threat to public health. Major difficulties with current chemotherapeutic agents raise issues such as toxicity, resistance, cost and other side effects. These issues necessitate development of potentially new chemical entities against diverse leishmanial species. Numerous natural and synthetic new antileishmanial molecules have been described for disease management. Careful inspection of scientific reports revealed that considerable amount of promising antileishmanial agents belonged to the nitrogen-containing heterocycles such as quinoline, triazole, pyrazole, imidazole, indole, pyrimidine, β-carboline, quinoxaline, quinazoline and benzimidazole. In this regard, enormous chemical data provide the opportunity for systematic elucidation of structural requirements against different leishmanial species. Within this representation, insights into the current status of privileged N -heterocycles as antileishmanial agents with particular emphasis on structure activity relationships are reviewed. Graphical abstract</description><subject>Animals</subject><subject>Antiprotozoal Agents - chemistry</subject><subject>Antiprotozoal Agents - pharmacology</subject><subject>Antiprotozoal Agents - therapeutic use</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Comprehensive Review</subject><subject>Health risks</subject><subject>Heterocyclic Compounds - chemistry</subject><subject>Heterocyclic Compounds - pharmacology</subject><subject>Heterocyclic Compounds - therapeutic use</subject><subject>Humans</subject><subject>Inspection</subject><subject>Leishmania - drug effects</subject><subject>Leishmaniasis - drug therapy</subject><subject>Life Sciences</subject><subject>Organic Chemistry</subject><subject>Pharmacy</subject><subject>Polymer Sciences</subject><subject>Public health</subject><subject>Toxicity</subject><issn>1381-1991</issn><issn>1573-501X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kF9LHDEUxYNUuqv2C_hQAn3pS_TeyWT-PBaxKkh9UfQtZDN3dmeZndnmZgS_fbOuVuhDSSCB-zsnOUeIU4QzBCjPGRE0KMBaQV0brfIDMUdTamUAnz6lu65QYV3jTBwxrwGSDPVnMdMIWWVMNRePNwN3y1Vk2Q1xlHFF0k8h0BAlRxcnlmMrt6F77npaUiN_qRVFCqN_8T2xdGkPMc06Xm3c0LleumUS84k4bF3P9OXtPBYPPy_vL67V7d3VzcWPW-V1aaLyCF4X1PpFk2ntK3KGoIW2zFxZFeXC56AbyrWGrGjyNuVpFpi3hakr8nVV6GPxfe-7DePviTjaTcee-t4NNE5sswyLFDUzeUK__YOuxykM6Xc7yuRYpZWobE_5MDIHam1Kv3HhxSLYXe12X7tNtdvX2u3O-uub9bTYUPNX8t5zAvQe4DQalhQ-3v6P7R_VE42j</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Razzaghi-Asl, Nima</creator><creator>Sepehri, Saghi</creator><creator>Ebadi, Ahmad</creator><creator>Karami, Pari</creator><creator>Nejatkhah, Negin</creator><creator>Johari-Ahar, Mohammad</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6127-2497</orcidid></search><sort><creationdate>20200501</creationdate><title>Insights into the current status of privileged N-heterocycles as antileishmanial agents</title><author>Razzaghi-Asl, Nima ; Sepehri, Saghi ; Ebadi, Ahmad ; Karami, Pari ; Nejatkhah, Negin ; Johari-Ahar, Mohammad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-c10c36efcbd233c8ea5e0f0f72a7867bc403de433026d4f381db14f6598ec9863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antiprotozoal Agents - chemistry</topic><topic>Antiprotozoal Agents - pharmacology</topic><topic>Antiprotozoal Agents - therapeutic use</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Comprehensive Review</topic><topic>Health risks</topic><topic>Heterocyclic Compounds - chemistry</topic><topic>Heterocyclic Compounds - pharmacology</topic><topic>Heterocyclic Compounds - therapeutic use</topic><topic>Humans</topic><topic>Inspection</topic><topic>Leishmania - drug effects</topic><topic>Leishmaniasis - drug therapy</topic><topic>Life Sciences</topic><topic>Organic Chemistry</topic><topic>Pharmacy</topic><topic>Polymer Sciences</topic><topic>Public health</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Razzaghi-Asl, Nima</creatorcontrib><creatorcontrib>Sepehri, Saghi</creatorcontrib><creatorcontrib>Ebadi, Ahmad</creatorcontrib><creatorcontrib>Karami, Pari</creatorcontrib><creatorcontrib>Nejatkhah, Negin</creatorcontrib><creatorcontrib>Johari-Ahar, Mohammad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular diversity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Razzaghi-Asl, Nima</au><au>Sepehri, Saghi</au><au>Ebadi, Ahmad</au><au>Karami, Pari</au><au>Nejatkhah, Negin</au><au>Johari-Ahar, Mohammad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insights into the current status of privileged N-heterocycles as antileishmanial agents</atitle><jtitle>Molecular diversity</jtitle><stitle>Mol Divers</stitle><addtitle>Mol Divers</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>24</volume><issue>2</issue><spage>525</spage><epage>569</epage><pages>525-569</pages><issn>1381-1991</issn><eissn>1573-501X</eissn><abstract>Leishmania, one of the most important neglected tropical diseases, is endemic in several regions of the world and hence regarded as a serious threat to public health. Major difficulties with current chemotherapeutic agents raise issues such as toxicity, resistance, cost and other side effects. These issues necessitate development of potentially new chemical entities against diverse leishmanial species. Numerous natural and synthetic new antileishmanial molecules have been described for disease management. Careful inspection of scientific reports revealed that considerable amount of promising antileishmanial agents belonged to the nitrogen-containing heterocycles such as quinoline, triazole, pyrazole, imidazole, indole, pyrimidine, β-carboline, quinoxaline, quinazoline and benzimidazole. In this regard, enormous chemical data provide the opportunity for systematic elucidation of structural requirements against different leishmanial species. Within this representation, insights into the current status of privileged N -heterocycles as antileishmanial agents with particular emphasis on structure activity relationships are reviewed. Graphical abstract</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>31028558</pmid><doi>10.1007/s11030-019-09953-4</doi><tpages>45</tpages><orcidid>https://orcid.org/0000-0001-6127-2497</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1381-1991
ispartof Molecular diversity, 2020-05, Vol.24 (2), p.525-569
issn 1381-1991
1573-501X
language eng
recordid cdi_proquest_miscellaneous_2216285254
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Animals
Antiprotozoal Agents - chemistry
Antiprotozoal Agents - pharmacology
Antiprotozoal Agents - therapeutic use
Biochemistry
Biomedical and Life Sciences
Comprehensive Review
Health risks
Heterocyclic Compounds - chemistry
Heterocyclic Compounds - pharmacology
Heterocyclic Compounds - therapeutic use
Humans
Inspection
Leishmania - drug effects
Leishmaniasis - drug therapy
Life Sciences
Organic Chemistry
Pharmacy
Polymer Sciences
Public health
Toxicity
title Insights into the current status of privileged N-heterocycles as antileishmanial agents
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T20%3A59%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insights%20into%20the%20current%20status%20of%20privileged%20N-heterocycles%20as%20antileishmanial%20agents&rft.jtitle=Molecular%20diversity&rft.au=Razzaghi-Asl,%20Nima&rft.date=2020-05-01&rft.volume=24&rft.issue=2&rft.spage=525&rft.epage=569&rft.pages=525-569&rft.issn=1381-1991&rft.eissn=1573-501X&rft_id=info:doi/10.1007/s11030-019-09953-4&rft_dat=%3Cproquest_cross%3E2215418181%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2215418181&rft_id=info:pmid/31028558&rfr_iscdi=true